Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F, Wagner E
Universitäts-Frauenklinik, Freiburg, F.R.G.
Eur J Cancer. 1992;28A(8-9):1432-7. doi: 10.1016/0959-8049(92)90538-d.
The varying tumorbiological behaviour of ovarian carcinomas probably influences operability, response to chemotherapy, being one of the most relevant prognostic factors. Because it is believed that an activation of the epidermal growth factor/transforming growth factor alpha (EGF/TGF alpha) signal pathway could be involved, we analysed the expression of epidermal growth factor receptor (EGFR) and TGF alpha with molecular-chemical, biochemical and immunohistochemical methods in 42 ovarian carcinomas, 4 ovarian metastasis, 2 other malignant ovarian tumours, and in 25 nonmalignant tissues (ovary, myometrium). No major rearrangements or amplification of the EGFR or TGF alpha genes were found. In non-malignant tissues no strong EGFR or TGF alpha signals were detected. TGF alpha is mainly produced by the tumour cells as shown by immunohistochemistry. Four different high molecular weight forms (20-48 kD) were detected in malignant tissues by western blot analysis.
卵巢癌不同的肿瘤生物学行为可能会影响其可切除性及对化疗的反应,这是最重要的预后因素之一。由于认为表皮生长因子/转化生长因子α(EGF/TGFα)信号通路的激活可能与之有关,我们采用分子化学、生物化学和免疫组织化学方法,分析了42例卵巢癌、4例卵巢转移瘤、2例其他恶性卵巢肿瘤及25例非恶性组织(卵巢、子宫肌层)中表皮生长因子受体(EGFR)和TGFα的表达。未发现EGFR或TGFα基因有重大重排或扩增。在非恶性组织中未检测到强EGFR或TGFα信号。免疫组织化学显示,TGFα主要由肿瘤细胞产生。通过蛋白质印迹分析在恶性组织中检测到四种不同的高分子量形式(20 - 48 kD)。